Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Entrepreneurs pitch limited access to experimental treatments as an economic and patient‑care opportunity
Summary
Supporters of HB1735 told the committee the bill would permit narrowly defined access to investigational or early‑phase treatments for patients with serious conditions and could attract biotech founders and clinics to New Hampshire; supporters framed the bill as patient choice with oversight; opponents were not prominent in the transcript.
Proponents of HB1735 presented it as a narrowly tailored bill to allow authorized access to investigational treatments—generally products that have completed early safety (phase 1) testing and are provided under clinical oversight—for patients with serious or chronic conditions who lack effective alternatives. Entrepreneurs and prospective…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
